NCT00373607View on ClinicalTrials.gov

Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru

PHASE3CompletedINTERVENTIONAL
Enrollment

522

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Malaria
Interventions
DRUG

Dihydroartemisin-piperaquine

Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine

DRUG

Mefloquine + Artesunate

Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day

All Listed Sponsors
lead

Institute of Tropical Medicine, Belgium

OTHER

NCT00373607 - Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru | Biotech Hunter | Biotech Hunter